Clinical Trial Update: A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib [Phase 2]

View source ↗

Summary

Phase 2 exploratory study of erlotinib in combination with SNDX-275 in non-small cell lung cancer patients progressing on erlotinib; trial terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• SNDX-275 (entinostat)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-07-06